Results 51 to 60 of about 19,732 (239)

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

open access: yesAdvanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu   +7 more
wiley   +1 more source

Future Application of Oncolytic Viruses for Cancer Treatment

open access: yes, 2023
Cancer treatments have developed over the years. A particular improvement is the utilization of oncolytic viruses to treat cancers. Oncolytic viruses are one of the immunotherapeutic tools that potentially could provide good results and benefits to the ...
Jo, Juandy   +3 more
core   +1 more source

Oncolytic virotherapy using neural stem cells as a novel treatment option for glioblastoma multiforme

open access: yesMedComm – Oncology, 2023
The most deadly and aggressive form of brain cancer is called a glioblastoma multiforme. Following diagnosis, the median duration of survival is only 14 months.
Tanvir Ahmed
doaj   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu   +4 more
wiley   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

open access: yesAdvanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård   +19 more
wiley   +1 more source

Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases

open access: yesMolecular Biology, 2022
Cancer is a leading causes of death. Despite significant success in the treatment of lymphatic system tumors, the problems of relapse, drug resistance and effectiveness of therapy remain relevant. Oncolytic viruses are able to replicate in tumor cells and destroy them without affecting normal, healthy tissues.
Vorobyev, P. O.   +6 more
openaire   +3 more sources

Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing

open access: yesAdvanced Science, EarlyView.
Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale   +6 more
wiley   +1 more source

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

open access: yesViruses, 2015
Oncolytic viruses represent a diverse class of replication competent viruses that curtail tumor growth. These viruses, through their natural ability or through genetic modifications, can selectively replicate within tumor cells and induce cell death ...
Karishma R. Rajani, Richard G. Vile
doaj   +1 more source

Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
ZIFOA‐M is engineered by conjugating oncolytic adenovirus‐loaded ZIF‐8 nanoparticles onto macrophage surfaces via bioorthogonal chemistry. Upon tumor infiltration, the platform releases OA to downregulate CD47/CD24 on tumor cells, restoring macrophage phagocytosis.
Jilong Wang   +10 more
wiley   +1 more source

Measles virus causes immunogenic cell death in human melanoma

open access: yes, 2011
NoOncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma.
Russell, S   +44 more
core   +1 more source

Home - About - Disclaimer - Privacy